Xconomy

OCTOBER 7, 2016

—Merrimack Pharmaceuticals (NASDAQ: MACK ) announced layoffs of 22 percent of its staff and the resignation of CEO Robert Mulroy. —San Diego: Biotech firm Sirenas reeled in a grant from the Bill and Melinda Gates Foundation to extract chemicals from marine organisms that might treat neglected diseases. CLINICAL NEWS.

Technical Review 77

Technical Review Study Layoffs San Diego 77

Xconomy

JULY 1, 2016

. —In the pink slip department, Cambridge-based Infinity Pharmaceuticals (NASDAQ: INFI ) announced 100 layoffs , more than half its workforce, after it terminated its partnership with AbbVie (NYSE: NYSE ) around the cancer drug duvelisib.

Buzzfeed 59

Buzzfeed News Pricing IBM 59

Xconomy

MAY 22, 2017

When Donald Trump heralded Ford’s announcement earlier this year that it would invest $1.2 billion in its Michigan plants, it was seen by some as the fulfillment of campaign promises to “bring jobs back” and put America first.

Report 55

Report Pricing Invest Artificial Inteligence 55

Xconomy

JUNE 30, 2017

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.

Writing 56

Writing Report Artificial Inteligence San Diego 56

Xconomy

SEPTEMBER 15, 2017

It was a week of realignments. President Trump, who used to be known as “The Donald” but now goes by “ Amnesty Don ,” kept up the parlay-voo with his new friends Chuck and Nancy. Martin Shkreli, who was once known— and still is!

Marketing 45

Marketing Venture Capital San Diego Study 45

Xconomy

MARCH 3, 2017

In an address to Congress this week, President Donald Trump outlined many of his near-term goals, including an overhaul of the Affordable Care Act, also known as Obamacare, even as public opinion has begun to shift in favor of the law.

San Diego 40

San Diego Pricing Layoffs Blogging 40

Xconomy

NOVEMBER 18, 2016

Speculation swirled this week around the incoming U.S. president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that naming-and-shaming—that is, Congress hauling executives into hearings and penning angry letters—certainly hasn’t done the trick.

News 40

News Press Pricing Report 40

Xconomy

DECEMBER 16, 2016

The 21st Century Cures Act is now law. New York wants to play in the biotech big leagues. The FDA under Trump will have license to approve drugs faster and could have a former top official back on board as commissioner. An eye drug failed, an Alzheimer’s drug got scrutinized, and a new antibiotic passed two key tests.

Funding 40

Funding San Diego Layoffs Blogging 40